Dopaminergic neurotoxicity of homocysteine and its derivatives in primary mesencephalic cultures

Journal of Neural Transmission, Supplement

Volumn , Issue 68, 2004, Pages 1-13

  Heider, I ^a   Lehmensiek, V ^a   Lenk, Th ^a   Muller Th ^b   Storch, A ^a,c  

^a UNIVERSITY OF ULM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; CYSTEIC ACID; HOMOCYSTEIC ACID; HOMOCYSTEINE; LEVODOPA; S ADENOSYLHOMOCYSTEINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL STRUCTURE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE EXACERBATION; DOPAMINERGIC NERVE CELL; HUMAN; IN VITRO STUDY; INCUBATION TIME; MESENCEPHALON; NERVE CELL CULTURE; NEURITE; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TOXICITY TESTING;

EID: 4544378765     PISSN: 03036995     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-7091-0579-5_1     Document Type: Article

References (50)

1. Allain P, Le Bouil A, Cardillet E, Le Quay L, Bagheri H, Montastruc JL (1995) Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 16: 527-529
2. Althausen S, Paschen W (2000) Homocysteine-induced changes in mRNA levels of genes coding for cytoplasmic- and endoplasmic reticulum-resident stress proteins in neuronal cell cultures. Brain Res Mol Brain Res 84(1-2): 32-40
3. Ben Shlomo Y, Marmot MG (1995) Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 58: 293-299
4. Blessing H, Bareiss M, Zettlmeisl H, Schwarz J, Storch A (2003) Catechol-O-methyltransferase inhibition protects against 3,4- dihydroxyphenylalanine (dopa) toxicity in primary mesencephalic cultures: new insights into levodopa toxicity. Neurochem Int 42(2): 139-151
5. Blunt SB, Jenner P, Marsden CD (1993) Suppressive effects of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 8: 129-133
6. Broch OJ, Ueland PM (1984) Regional distribution of homocysteine in the mammalian brain. J Neurochem 43(6): 1755-1757
7. Buemi M, Marino D, Di Pasquale G, Floccari F, Ruello A, Aloisi C, Corica F, Senatore M, Romeo A, Frisina N (2001) Effects of homocysteine on proliferation, necoris and apoptosis of vascular smooth muscle cells in culture and influence of folic acid. Thromb Res 104: 207-213
8. Chambers JC, McGregor A, Kooners JS (1998) Acute hyperhomocysteinaemia and endothelial dysfanction. Lancet 351: 36-37
9. Chen C, Halkos ME, Surowiec SM, Conklin BS, Lin PH, Lumsden AB (2000) Effects of homocysteine on smooth muscle cell proliferation in both cell culture and artery perfusion culture models. J Surg Res 88: 26-33
10. Duan W, Zhang Z, Gash DM, Mattson MP (1999) Participation of prostate apoptosis response-4 in degeneration of dopaminergic neurons in models of Parkinson's disease. Ann Neurol 46: 587-597
11. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP (2002) Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 80: 101-110
12. Fahn S, Parkinson's Study Group (2002) Results of the ELLDOPA (Earlier vs. Later levodopa) study. Mov Disord 17 [Suppl 5]: S13
13. Goetz CG (1998) Influence of COMT inhibition on levodopa pharmacology and therapy. Neurology 50 [Suppl 5]: S26-S30
14. Gorell JM, Johnson CC, Rybicki BA (1994) Parkinson's disease and its comorbid disorders: an analysis of Michigan martality data, 1970 to 1990. Neurology 44: 1865-1868
15. Ho PI, Collins SC, Dhitavat S, Ortiz D, Ashline D, Rogers E, Shea TB (2001) Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem 78(2): 249-253
16. Ho PI, Ortiz D, Rogers E, Shea TB (2002) Multiple aspects of homocysteine neurotoxicity: glutamate excitotoxicity, kinase hyperactivation and DNA damage. J Neurosci Res 70(5): 694-702
17. Jara-Prado A, Ortega-Vazquez A, Martinez-Ruano L, Rios C, Santamaria A (2003) Homocysteine-induced brain lipid peroxidation: effects of NMDA receptor blockade, antioxidant treatment, and nitric oxide synthase inhibition. Neurotox Res 5(4): 237-243
18. Jeffrey D, Roth JA (1984) Characterization of membrane-bound and soluble catechol-O-methyltransferase from human frontal cortex. J Neurochem 24(3): 826-832
19. Kim WK, Pae YS (1996) Involvement of N-methyl-D-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture. Neurosci Lett 216(2): 117-120
20. Klockgether T, Turski L, Honore T, Zhang ZM, Gash DM, Kurlan R, Greenamyre JT (1991) The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine depleted rats and MPTP-treated monkeys. Ann Neurol 30: 717-723
21. + in co-cultures from mesencephalon and striatum of embryonic C57BL/6 mice. J Neurosci Res 41: 197-205
22. Kruman II, Kumaravel TS, Lohani A, Pedersen WA, Cutler RG, Kruman Y, Haughey N, Lee J, Evans M, Mattson MP (2002) Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22(5): 1752-1762
23. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Müller T (1998) Hyperhomocysteinaemia in Parkinson's disease. J Neurol 245: 811-812
24. Lang AE, Lozano AM (1998) Parkinson's disease. N Engl J Med 339: 1044-1053; 1130-1143
25. Lindgren A, Brattstrom L, Norrving B, Hultberg B, Andersson A, Johansson BB (1995) Plasma homocysteine in the acute and convalescent phases after stroke. Stroke 26(5): 795-800
26. Lipton SA, Kim WK, Choi YB, Kumar S, D'Emilia DM, Rayudu PV, Arnelle DR, Stamler JS (1997) Neurotoxicity associated with dual actions of homocystein at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 94: 5923-5928
27. Liu XX, Wilson K, Charlton CG (2000) Effects of L-Dopa treatment on methylation in mouse brain: implications for the side effects of L-dopa. Life Sci 66: 2277-2288
28. Loschmann PA, Lange KW, Wachtel H, Turski L (1994) MPTP-induced degeneration: interference with glutamatergic toxicity. J Neural Transm [Suppl] 43: 133-143
29. Luquin R, Del Rio L, Saldise L, Setuain J, Manzi B (2001) Levodopa but not pergolide administration induces apoptosis in the substantia nigra neurons of rats with partial nigrostriatal lesion. Neurology 56 [Suppl 3]: A378
30. Mannistö PT, Tuomainen P (1991) Effect of high single doses of levodopa and carbidopa on brain dopamine and its metabolites: modulation by selective inhibitors of monoamine oxidase and/or catechol-O-methyltransferase in the male rat. Naunyn Schmiedebergs Arch Pharmacol 344(4): 412-418
31. Männistö PT, Ulmanen I, Lundström K, Taskinen J, Tenhunen J, Tilgmann C, Kaakkola S (1992) Characteristics of catechol O-methyl transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 39: 291-350
32. Mena MA, Pardo B, Casarejos MJ, Fahn S, De Yebenes JG (1992) Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disord 7: 23-31
33. Mena MA, Pardo B, Paino CL, De Yebenes JG (1993) Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid. NeuroReport 4(4): 438-440
34. Menzies FM, Cookson MR, Taylor RW, Turnbull DM, Chrzanowska-Lightowlers ZM, Dong L, Figlewicz DA, Shaw PJ (2002) Mitochondrial dysfunction in a cell model of familial amyotrophic lateral sclerosis. Brain 125: 1522-1533
35. +) in rat dissociated mesencephalic cultures. Brain Res 597: 233-240
36. Michel PP, Dandapani BK, Knusel B, Sanchez-Ramos J, Hefti F (1990) Toxicity of l-methyl-4-phenylpyridinium for rat dopaminergic neurons in culture: selectivity and irreversibility. J Neurochem 54: 1102-1109
37. Miller JW, Shukitt-Hale B, Villalobos-Molina R, Nadeau MR, Selhub J, Joseph JA (1997) Effect of L-Dopa and the catechol-O-methyltrasnferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats. Clin Neuropharmacol 20: 55-66
38. Müller T, Werne B, Fowler B, Kuhn W (1999) Nigral endothelial dysfunction, homocystein, and Parkinson's disease. Lancet 354: 126-127
39. Müller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W (2001) Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 308: 54-56
40. Parsons RB, Waring RH, Ramsden DB, Williams AC (1998) In vitro effects of cysteine metabolites homocysteic acid, homocysteine and cysteic acid upon human neuronal cell lines. Neurotoxicology 19: 599-603
41. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG (1995) Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 346: 1395-1398
42. Selhub J, Jacques PF, Bostom AG, D'Agostino RB, Wilson PW, Belanger AJ, O'Leary DH, Wolf PA, Schaefer EJ, Rosenberg IH (1995) Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med 332(5): 286-291
43. Storch A, Blessing H, Bareiss M, Jankowski S, Ling ZD, Carvey P, Schwarz J (2000a) Catechol-O-methyltransferase inhibition attenuates levodopa toxicity in mesencephalic dopamine neurons. Mol Pharmacol 57: 589-594
44. Storch A, Burkhardt K, Ludolph AC, Schwarz J (2000) Protective effects of riluzole on dopamine neurons: involvement of oxidative stress and cellular energy metabolism. J Neurochem 75(6): 2259-2269
45. Tolosa E, Marti MJ, Valldeoriola F, Molinuevo JL (1998) History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 50 [Suppl 6]: S2-S10
46. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349: 414-418
47. White AR, Huang X, Jobling MF, Barrow CJ, Beyreuther K, Masters CL, Bush AI, Cappai R (2001) Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem 76(5): 1509-1520
48. Wurtman RJ (1972) Effect of L-dopa on S-adenosylmethionine levels and norepinephrine metabolism in rat brain. In: Costa E, Iversen LL, Paoletti R (eds) Advances in biochemical psychopharmacology, vol 6. Raven Press, New York, pp 241-246
49. Yassin MS, Cheng H, Ekblom J, Oreland L (1998) Inhibitors of catecholamine metabolizing enzymes cause changes in S-adenosylmethionine and S-adenosylhomocystein in the rat brain. Neurochem Int 32: 53-59
50. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K (2000) Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 55: 437-440